Judith A E M Zecha1, Judith E Raber-Durlacher1,2, Raj G Nair3, Joel B Epstein4,5, Sharon Elad6, Michael R Hamblin7,8,9, Andrei Barasch10, Cesar A Migliorati11, Dan M J Milstein1, Marie-Thérèse Genot12, Liset Lansaat13, Ron van der Brink5, Josep Arnabat-Dominguez14, Lisette van der Molen13, Irene Jacobi13, Judi van Diessen15, Jan de Lange1, Ludi E Smeele1,13, Mark M Schubert16, René-Jean Bensadoun17. 1. Department of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands. 2. Department of Medical Dental Interaction and Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, P.O. Box 22660 1100 DD, Amsterdam, the Netherlands. 3. Oral Medicine Oral Pathology and Human Diseases, Menzies Health Institute Queensland and Oral Medicine Consultant, Department of Haematology and Oncology/Cancer Services, Gold Coast University Hospital, Queensland Health, Queensland, Australia. 4. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 5. Division of Otolaryngology and Head and Neck Surgery, City of Hope, Duarte, CA, 91010, USA. 6. Division of Oral Medicine, Eastman Institute for Oral Health, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, 14620, USA. 7. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA. 8. Department of Dermatology, Harvard Medical School, Boston, MA, 02115, USA. 9. Harvard-MIT Division of Health Science and Technology, Cambridge, MA, 02139, USA. 10. Division of Oncology, Weill Cornell Medical Center, New York, NY, USA. 11. Department of Diagnostic Sciences and Oral Medicine, Director of Oral Medicine, College of Dentistry, University of Tennessee Health Science Center, 875 Union Ave. Suite N231, Memphis, TN, 38163, USA. 12. Laser Therapy Unit, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium. 13. Antoni van Leeuwenhoek Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands. 14. Department of Oral Surgery, Faculty of Dentistry, University of Barcelona, Barcelona, Spain. 15. Antoni van Leeuwenhoek Department of Radiation Oncology, Amsterdam, Netherlands Cancer Institute, Amsterdam, the Netherlands. 16. Seattle Cancer Care Alliance (SCCA), Oral Medicine, 825 Eastlake Ave E Ste G6900, Seattle, WA, 98109, USA. 17. World Association for Laser Therapy (WALT) Scientific Secretary, Centre de Haute Energie (CHE), 10 Bd Pasteur, 06000, Nice, France. renejean.bensadoun@che-nice.com.
Abstract
PURPOSE: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed. METHODS: Narrative review and presentation of PBM parameters are based on current evidence and expert opinion. RESULTS: PBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780-830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2-3 J (J/cm(2)), and no more than 6 J/cm(2) on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (<100 Hz); and route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations. CONCLUSION: PBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.
PURPOSE: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed. METHODS: Narrative review and presentation of PBM parameters are based on current evidence and expert opinion. RESULTS:PBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780-830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2-3 J (J/cm(2)), and no more than 6 J/cm(2) on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (<100 Hz); and route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations. CONCLUSION:PBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.
Entities:
Keywords:
Chemotherapy; Head and neck cancer; LLLT; Low-level laser therapy; Low-level light therapy; Mucositis; Orofacial complications; PBM; Photobiomodulation; Radiation therapy
Authors: Jonas D Batista; Darceny Zanetta-Barbosa; Sérgio V Cardoso; Paula Dechichi; Flaviana S Rocha; Rogério M Pagnoncelli Journal: Lasers Med Sci Date: 2014-06-10 Impact factor: 3.161
Authors: Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2008-09-30 Impact factor: 2.503
Authors: Cesar Migliorati; Ian Hewson; Rajesh V Lalla; Heliton Spindola Antunes; Cherry L Estilo; Brian Hodgson; Nilza Nelly Fontana Lopes; Mark M Schubert; Joanne Bowen; Sharon Elad Journal: Support Care Cancer Date: 2012-09-22 Impact factor: 3.603
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Letícia Mello Bezinelli; Luciana Corrêa; Cristina Vogel; Jose Mauro Kutner; Andreza Feitosa Ribeiro; Nelson Hamerschlak; Carlos de Paula Eduardo; Cesar Augusto Migliorati; Fernanda de Paula Eduardo Journal: Support Care Cancer Date: 2021-05-22 Impact factor: 3.603
Authors: Sharon Elad; Praveen Arany; Rene-Jean Bensadoun; Joel B Epstein; Andrei Barasch; Judith Raber-Durlacher Journal: Support Care Cancer Date: 2018-05-22 Impact factor: 3.603
Authors: Caroline de Bataille; Vincent Sibaud; Angélique Prioul; Anne Laprie; Emmanuelle Vigarios Journal: Support Care Cancer Date: 2017-10-09 Impact factor: 3.603
Authors: Joel B Epstein; Paul Y Song; Allen S Ho; Babak Larian; Arash Asher; Rene-Jean Bensadoun Journal: Support Care Cancer Date: 2016-12-17 Impact factor: 3.603
Authors: Jolien Robijns; Sandrine Censabella; Stefan Claes; Luc Pannekoeke; Lore Bussé; Dora Colson; Iris Kaminski; Joy Lodewijckx; Paul Bulens; Annelies Maes; Leen Noé; Marc Brosens; An Timmermans; Ivo Lambrichts; Veerle Somers; Jeroen Mebis Journal: Support Care Cancer Date: 2018-10-01 Impact factor: 3.603
Authors: Joel B Epstein; Judith E Raber-Durlacher; Michael Lill; Yuliya P L Linhares; Jerry Chang; Andrei Barasch; Romée I C Slief; Margot Geuke; Judith A E M Zecha; Dan M J Milstein; D Tzachanis Journal: Support Care Cancer Date: 2016-09-21 Impact factor: 3.603